Figure 4.
Enrichment of gene fusions in patients with gastric cancer with driver alterations. A: The incidence of gene fusions in patients with and without driver alterations were analyzed, P > 0.05; B: The incidence of gene fusions in patients with and without ERBB2 amplifications were analyzed, P < 0.05; C: The incidence of gene fusions in patients with microsatellite instability-high and microsatellite stability were analyzed, P > 0.05; D: Tumor mutational burden in targetable gene fusion-positive and -negative patients was compared, P > 0.05.
